PURE Bioscience Announces Co-Marketing and Supply Agreement with Roka Bioscience, Inc.
July 10 2017 - 8:36AM
Business Wire
PURE Bioscience, Inc. (OTCQB: PURE),
creator of the patented non-toxic silver dihydrogen citrate (SDC)
antimicrobial, today announced that it has entered into a two-year
nonexclusive supply agreement with Roka Bioscience, Inc. (NASDAQ:
ROKA) for Roka to market PURE’s line of antimicrobial disinfecting
and sanitizing products and processing aids to the food industry.
Roka is a molecular diagnostics company focused on providing
advanced testing solutions for the detection of foodborne
pathogens.
With this Agreement PURE Bioscience expands Roka Bioscience’s
reach into the operational environments of food production with
environmental and surface disinfectants and processing
interventions for pathogen control, complementing their Atlas
foodborne pathogen testing portfolio.
Hank R. Lambert, CEO of PURE said, “We are very excited to
partner with Roka in offering advanced science in both pathogen
detection and elimination to the food industry. Our proven silver
dihydrogen citrate based antimicrobial solutions have been adopted
by Chipotle, Taylor Farms, Subway® and numerous other food
companies for effective pathogen reduction. Partnering with Roka
will enable us to extend our solutions to their broad customer
portfolio.”
Mary Duseau, CEO of Roka Bioscience stated, “Roka Bioscience
continues to deliver technology forward solutions to the food
industry. With the addition of the PURE Bioscience product line,
Roka’s commitment to food safety now extends from the processing
floor to the laboratory. We believe that this partnership and
our solution approach offers the industry increased control and
resolution in pathogen detection and prevention.”
About Roka BioscienceRoka Bioscience is a molecular
diagnostics company focused on developing and commercializing
advanced testing solutions for the food safety testing market. Our
Atlas® Detection Assays incorporate our advanced molecular
technologies and are performed on our "sample-in, result-out"
Atlas® System that automates all aspects of molecular diagnostic
testing on a single, integrated platform. The Atlas® System and
Detection Assays are designed to provide our customers with
accurate and rapid test results with reduced labor costs and
improved laboratory efficiencies. For more information,
visit http://rokabio.com.
About PURE Bioscience, Inc.PURE Bioscience, Inc. is
focused on developing and commercializing our proprietary
antimicrobial products primarily in the food safety arena --
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum,
non-toxic antimicrobial agent, which offers 24-hour residual
protection and formulates well with other compounds. As a platform
technology, SDC is distinguished from existing products in the
marketplace because of its superior efficacy, reduced toxicity and
it mitigates bacterial resistance. PURE is headquartered in El
Cajon, California (San Diego metropolitan area). Additional
information on PURE is available at www.purebio.com.
Forward-looking StatementsAny statements contained in
this press release that do not describe historical facts may
constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause our actual results to differ
materially from any forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, the Company’s failure to implement or otherwise achieve
the benefits of its proposed business initiatives and plans;
acceptance of the Company's current and future products and
services in the marketplace, including the Company’s ability to
convert successful evaluations and tests into customer orders and
customers continuing to place product orders as expected and to
expand their use of the Company’s products; the ability of the
Company to develop effective new products and receive required
regulatory approvals for such products, including the required data
and regulatory approvals required to use its SDC-based technology
as a direct food contact processing aid in raw meat processing and
to expand its use in OLR poultry processing; the Company’s ability
to raise funds necessary to support its continued operations and
the implementation of its business plan; competitive factors;
dependence upon third-party vendors, including to manufacture its
products; and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission (the SEC),
including its Form 10-K for the fiscal year ended July 31, 2016,
its Form 10-Q for the first quarter ended October 31, 2016 and
third quarter ended April 30, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170710005175/en/
PURE Bioscience, Inc.Hank Lambert, CEO619-596-8600
ext.103hlambert@purebio.comorBibicoff + MacInnis, Inc.Terri
MacInnis, VP of IR818-379-8500terri@bibimac.comorRedwood Investment
GroupTom Hemingway714-978-4425tomh@redwoodfin.com
ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ROKA BIOSCIENCE, INC. (NASDAQ:ROKA)
Historical Stock Chart
From Apr 2023 to Apr 2024